[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-hypercholesterolaemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-hypercholesterolaemia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100608816","a-study-of-bempedoic-acid-or-its-single-pill-combination-therapy-with-ezetimibe-in-patients-with-primary-hypercholesterolaemia-or-mixed-dyslipidaemia-100608816",false,"NCT07206472","A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia","A Multi-national, Non-interventional Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia","Musashi","Patients can be enrolled, when they fulfil the following inclusion criteria:\n\n* Written informed consent to participate.\n* At least 18 years of age.\n* Patients suffering from documented primary hypercholesterolemia or mixed dyslipidaemia treated or intended to be treated with bempedoic acid\u002F FDC with ezetimibe at the discretion of the physician are appropriate for participation in the observation.\n* For patients who are treated with bempedoic acid\u002FFDC with ezetimibe prior to signed informed consent, initiation of bempedoic acid\u002FFDC with ezetimibe must be within a maximum of three months prior to inclusion.\n* No contraindications exist according to the SmPC of bempedoic acid\u002FFDC with ezetimibe.\n* No concurrent participation in an interventional study (simultaneous participation in other non-interventional study is possible)\n* Life expectancy \\> 1 year.\n\nNo explicit exclusion criteria exist to avoid selection bias and to allow for documentation of routine clinical practice.","ALL","18 Years",{"count":20,"type":21},2120,"ESTIMATED","OBSERVATIONAL","There is limited efficacy and safety data of bempedoic acid or its fixed dose combination (FDC) with ezetimibe in Asian and Latin American patients. This non-interventional study (NIS) will be conducted to characterize the risks and benefits of bempedoic acid or FDC with ezetimibe in a real-world clinical setting in adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.",[25,26],"Primary Hypercholesterolaemia","Mixed Dyslipidemia",[28,29],"Primary hypercholesterolemia","Mixed dyslipidemia","RECRUITING","2026-07-30",{"date":33,"type":34},"2026-07-31","ACTUAL",{"date":36,"type":34},"2026-03-03",{"date":38,"type":21},"2028-12-31",{"name":40,"class":41},"Daiichi Sankyo","INDUSTRY",23,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100584035","phase-1-a-study-to-compare-pk-characteristics-and-safety-profiles-between-ad-228b-and-ad-2284-100584035","NCT06884098","A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284","An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Bioequivalence of AD-228B with AD-2284 in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in other clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"19 Years",{"count":53,"type":21},60,"INTERVENTIONAL",[56],"PHASE1","Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.",[25],"2025-03-18",{"date":61,"type":34},"2025-03-20",{"date":63,"type":34},"2025-03-10",{"date":65,"type":21},"2025-04",{"name":67,"class":41},"Addpharma Inc.",1]